Clinical trial
A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita
NCT03920228 is registered in ClinicalTrials.gov with Palvella Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita
- Lead sponsor
- Palvella Therapeutics, Inc.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- April 1, 2019
- Completion date
- October 19, 2020
- Enrollment
- 73 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.